BACKGROUND: Literature on the effects of prenatal exposure to platinum-based chemotherapy on the auditory capacity of the offspring is scarce. The current study aims to describe the occurrence of hearing impairment in a well-documented series of children who underwent audiological testing. METHODS: An international, descriptive multicentre study using oncological, obstetrical, and neonatal data registered by the International Network of Cancer Infertility and Pregnancy database, was performed. The offspring (aged ≥ 4 years) underwent pure tone audiometry. Audiological outcomes were registered after expert review, using international standardized audiological grading as developed for platinum exposed childhood cancer patients: the Muenster criteria and the International Society for Paediatric Oncology classification. Platinum-induced hearing loss was defined as bilateral hearing loss, starting at 8 kHz and without middle ear problems confirmed by tympanometry or otoscopy. FINDINGS: Twenty-five children were included of which 17 children (68%) had been exposed to cisplatin and 8 (32%) to carboplatin, none to both. Median gestational age at start maternal treatment was 22 weeks (range, 14–31). Median gestational age at delivery was 35 weeks (range, 31–39), and median birth weight was 2345 g (range, 1526–3360). Neonatal hearing screening, performed in 10 children (40%), showed no hearing loss. At a median age of 6.0 years (range, 4.0–28.0), 6 children (24%) revealed bilateral hearing loss, using cut-off values of Muenster grade ≥ 2b and SIOP grade ≥ 2. INTERPRETATION: Antenatal exposure to platinum-based chemotherapy is associated with hearing loss in a subset of the offspring. Prospective longitudinal standardized surveillance of auditory function is advised, starting after birth. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12887-025-05992-z.

Amsterdam UMC Emma Children's Hospital Amsterdam the Netherlands

Center for Gynecologic Oncology Amsterdam The Netherlands Cancer Institute Amsterdam the Netherlands

Department of Development and Regeneration Unit of Woman and Child KU Leuven Leuven Belgium

Department of Obstetrics and Gynaecology Unit of Foetomaternal Medicine University Hospitals Leuven Leuven Belgium

Department of Obstetrics and Gynecology 3Rd Medical Faculty Charles University and University Hospital Kralovske Vinohrady Prague Czech Republic

Department of Otorhinolaryngology 3Rd Medical Faculty Charles University and University Hospital Kralovske Vinohrady Prague Czech Republic

Department of Otorhinolaryngology Head and Neck Surgery University Medical Centre Utrecht UMC Brain Centre Utrecht The Netherlands

Division Gynecologic Oncology University Hospitals Leuven UZ Gasthuisberg Herestraat 49 Leuven 3000 Belgium

Princess Máxima Center for Pediatric Oncology Utrecht the Netherlands

University Medical Center Utrecht Wilhelmina Children's Hospital Utrecht The Netherlands

Zobrazit více v PubMed

Parazzini F, Franchi M, Tavani A, Negri E, Peccatori FA. Frequency of pregnancy related cancer: a population based linkage study in Lombardy, Italy. Int J Gynecol Cancer. 2017;27(3):613–9. PubMed

Amant F, Han SN, Gziri MM, Vandenbroucke T, Verheecke M, Van Calsteren K. Management of cancer in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2015;29(5):741–53. PubMed

Boere I, Lok C, Vandenbroucke T, Amant F. Cancer in pregnancy: safety and efficacy of systemic therapies. Curr Opin Oncol. 2017;29(5):328–34. PubMed

Amant F, Van Calsteren K, Halaska MJ, Gziri MM, Hui W, Lagae L, et al. Long-term cognitive and cardiac outcomes after prenatal exposure to chemotherapy in children aged 18 months or older: an observational study. Lancet Oncol. 2012;13(3):256–64. PubMed

Amant F, Vandenbroucke T, Verheecke M, Fumagalli M, Halaska MJ, Boere I, et al. Pediatric outcome after maternal cancer diagnosed during pregnancy. N Engl J Med. 2015;373(19):1824–34. PubMed

Blommaert J, Radwan A, Sleurs C, Maggen C, van Gerwen M, Wolters V, et al. The impact of cancer and chemotherapy during pregnancy on child neurodevelopment: a multimodal neuroimaging analysis. EClinicalMedicine. 2020;28:100598. PubMed PMC

Vandenbroucke T, Verheecke M, van Gerwen M, Van Calsteren K, Halaska MJ, Fumagalli M, et al. Child development at 6 years after maternal cancer diagnosis and treatment during pregnancy. Eur J Cancer. 2020;138:57–67. PubMed PMC

Maggen C, van Gerwen M, Van Calsteren K, Vandenbroucke T, Amant F. Management of cancer during pregnancy and current evidence of obstetric, neonatal and pediatric outcome: a review article. Int J Gynecol Cancer. 2019;29(2):404–16. PubMed

Van Calsteren K, Verbesselt R, Van Bree R, Heyns L, de Bruijn E, de Hoon J, et al. Substantial variation in transplacental transfer of chemotherapeutic agents in a mouse model. Reprod Sci. 2011;18(1):57–63. PubMed

Sheth S, Mukherjea D, Rybak LP, Ramkumar V. Mechanisms of cisplatin-induced ototoxicity and otoprotection. Front Cell Neurosci. 2017;11:338. PubMed PMC

Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003;22(47):7265–79. PubMed

Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev. 2007;33(1):9–23. PubMed PMC

Clemens E, de Vries AC, Pluijm SF, Am Zehnhoff-Dinnesen A, Tissing WJ, Loonen JJ, et al. Determinants of ototoxicity in 451 platinum-treated Dutch survivors of childhood cancer: a DCOG late-effects study. Eur J Cancer. 2016;69:77–85. PubMed

Clemens E, van den Heuvel-Eibrink MM, Mulder RL, Kremer LCM, Hudson MM, Skinner R, et al. Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium. Lancet Oncol. 2019;20(1):e29–41. PubMed PMC

Travis LB, Fossa SD, Sesso HD, Frisina RD, Herrmann DN, Beard CJ, et al. Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics. J Nat Cancer Inst. 2014;106(5):dju044. PubMed PMC

Qaddoumi I, Bass JK, Wu J, Billups CA, Wozniak AW, Merchant TE, et al. Carboplatin-associated ototoxicity in children with retinoblastoma. J Clin Oncol. 2012;30(10):1034–41. PubMed PMC

Meijer AJM, Li KH, Brooks B, Clemens E, Ross CJ, Rassekh SR, et al. The cumulative incidence of cisplatin-induced hearing loss in young children is higher and develops at an early stage during therapy compared with older children based on 2052 audiological assessments. Cancer. 2022;128(1):169–79. PubMed

Brock PR, Maibach R, Childs M, Rajput K, Roebuck D, Sullivan MJ, et al. Sodium thiosulfate for protection from cisplatin-induced hearing loss. N Engl J Med. 2018;378(25):2376–85. PubMed PMC

Freyer DR, Chen L, Krailo MD, Knight K, Villaluna D, Bliss B, et al. Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2017;18(1):63–74. PubMed PMC

Knight KR, Chen L, Freyer D, Aplenc R, Bancroft M, Bliss B, et al. Group-wide, prospective study of ototoxicity assessment in children receiving cisplatin chemotherapy (ACCL05C1): a report from the children’s oncology group. J Clin Oncol. 2017;35(4):440–5. PubMed PMC

Terheggen PM, Begg AC, Emondt JY, Dubbelman R, Floot BG, den Engelse L. Formation of interaction products of carboplatin with DNA in vitro and in cancer patients. Br J Cancer. 1991;63(2):195–200. PubMed PMC

Landier W, Knight K, Wong FL, Lee J, Thomas O, Kim H, et al. Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales–a report from the children’s oncology group. J Clin Oncol. 2014;32(6):527–34. PubMed PMC

Rajput K, Edwards L, Brock P, Abiodun A, Simpkin P, Al-Malky G. Ototoxicity-induced hearing loss and quality of life in survivors of paediatric cancer. Int J Pediatr Otorhinolaryngol. 2020;138:110401. PubMed

Harvey LA. REDCap: web-based software for all types of data storage and collection. Spinal Cord. 2018;56(7):625. PubMed

Jerger J. Clinical experience with impedance audiometry. Arch Otolaryngol. 1970;92(4):311–24. PubMed

Brock PR, Knight KR, Freyer DR, Campbell KC, Steyger PS, Blakley BW, et al. Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale. J Clin Oncol. 2012;30(19):2408–17. PubMed PMC

Schmidt CM, Bartholomaus E, Deuster D, Heinecke A, Dinnesen AG. The “Muenster classification” of high frequency hearing loss following cisplatin chemotherapy. HNO. 2007;55(4):299–306. PubMed

Geijteman ECT, Wensveen CWM, Duvekot JJ, van Zuylen L. A child with severe hearing loss associated with maternal cisplatin treatment during pregnancy. Obstet Gynecol. 2014;124(2 Pt 2 Suppl 1):454–6. PubMed

Knight KR, Kraemer DF, Neuwelt EA. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol. 2005;23(34):8588–96. PubMed

Aquino VM, Fort DW, Kamen BA. Carboplatin for the treatment of children with newly diagnosed optic chiasm gliomas: a phase II study. J Neurooncol. 1999;41(3):255–9. PubMed

Kim SB, Kim SY, Kim KH, Kim TN. Oxaliplatin-induced sudden hearing loss in a patient with pancreatic cancer. Korean J Gastroenterol. 2020;76(5):261–4. PubMed PMC

Budai B, Prekopp P, Noszek L, Kovacs ER, Szonyi M, Erdelyi DJ, et al. GSTM1 null and GSTT1 null: predictors of cisplatin-caused acute ototoxicity measured by DPOAEs. J Mol Med (Berl). 2020;98(7):963–71. PubMed PMC

Al-Saleh E, Al-Harmi J, Nandakumaran M, Al-Shammari M. Transport kinetics of cisplatin in the perfused human placental lobule in vitro. J Matern Fetal Neonatal Med. 2008;21(10):726–31. PubMed

Rybak LP, Mukherjea D, Jajoo S, Ramkumar V. Cisplatin ototoxicity and protection: clinical and experimental studies. Tohoku J Exp Med. 2009;219(3):177–86. PubMed PMC

Hill GW, Morest DK, Parham K. Cisplatin-induced ototoxicity: effect of intratympanic dexamethasone injections. Otol Neurotol. 2008;29(7):1005–11. PubMed PMC

Marshak T, Steiner M, Kaminer M, Levy L, Shupak A. Prevention of cisplatin-induced hearing loss by intratympanic dexamethasone: a randomized controlled study. Otolaryngol Head Neck Surg. 2014;150(6):983–90. PubMed

Diepstraten FA, Hoetink AE, van Grotel M, Huitema ADR, Stokroos RJ, van den Heuvel-Eibrink MM, et al. Aminoglycoside- and glycopeptide-induced ototoxicity in children: a systematic review. JAC-Antimicrobial Resistance. 2021;3(4):dlab184. PubMed PMC

Meijer AJM, van den Heuvel-Eibrink MM, Brooks B, Am Zehnhoff-Dinnesen AG, Knight KR, Freyer DR, et al. Recommendations for age-appropriate testing, timing, and frequency of audiologic monitoring during childhood cancer treatment: an international society of paediatric oncology supportive care consensus report. JAMA Oncol. 2021;7(10):1550–8. PubMed

Hille ET, van Straaten HI, Verkerk PH, Dutch NNHSWG. Prevalence and independent risk factors for hearing loss in NICU infants. Acta Paediatr. 2007;96(8):1155–8. PubMed

Wheeler HE, Gamazon ER, Frisina RD, Perez-Cervantes C, El Charif O, Mapes B, et al. Variants in WFS1 and other mendelian deafness genes are associated with cisplatin-associated ototoxicity. Clin Cancer Res. 2017;23(13):3325–33. PubMed PMC

Clemens E, van der Kooi ALF, Broer L, van Dulmen-den BE, Visscher H, Kremer L, et al. The influence of genetic variation on late toxicities in childhood cancer survivors: a review. Crit Rev Oncol Hematol. 2018;126:154–67. PubMed

Meijer AJM, Diepstraten FA, Langer T, Broer L, Domingo IK, Clemens E, et al. TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study. NPJ Precis Oncol. 2021;5(1):64. PubMed PMC